We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Analysts on Wall Street project that Novartis (NVS - Free Report) will announce quarterly earnings of $1.67 per share in its forthcoming report, representing an increase of 10.6% year over year. Revenues are projected to reach $11.69 billion, declining 7.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Novartis metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Solid Tumors- Kisqali - Total' will reach $608.07 million. The estimate indicates a year-over-year change of +70.3%.
Based on the collective assessment of analysts, 'Revenues- Solid Tumors- Tafinlar + Mekinist - Total' should arrive at $502.28 million. The estimate points to a change of +8% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Neuroscience- Gilenya - Total' should come in at $231.53 million. The estimate points to a change of -33.1% from the year-ago quarter.
Analysts forecast 'Revenues- Immunology-Cosentyx - Total' to reach $1.34 billion. The estimate indicates a year-over-year change of +23.7%.
The combined assessment of analysts suggests that 'Revenues- Hematology- Tasigna - US' will likely reach $228.84 million. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Hematology- Promacta/Revolade - US' reaching $263.34 million. The estimate points to a change of -6.6% from the year-ago quarter.
Analysts predict that the 'Revenues- Neuroscience- Gilenya - US' will reach $104.73 million. The estimate suggests a change of -44.6% year over year.
Analysts expect 'Revenues- Immunology- Cosentyx - US' to come in at $723.22 million. The estimate suggests a change of +14.3% year over year.
The consensus estimate for 'Revenues- Cardiovascular- Entresto - US' stands at $839.24 million. The estimate indicates a change of +20.9% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Hematology- Tasigna - Rest of the world' of $233.24 million. The estimate indicates a change of -7.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Solid Tumors- Tafinlar + Mekinist - Rest of the world' will reach $296.24 million. The estimate points to a change of +2.2% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Hematology- Promacta/Revolade - Rest of the world' at $256.79 million. The estimate suggests a change of -0.5% year over year.
Over the past month, shares of Novartis have returned +7% versus the Zacks S&P 500 composite's +3.1% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Analysts on Wall Street project that Novartis (NVS - Free Report) will announce quarterly earnings of $1.67 per share in its forthcoming report, representing an increase of 10.6% year over year. Revenues are projected to reach $11.69 billion, declining 7.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Novartis metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Revenues- Solid Tumors- Kisqali - Total' will reach $608.07 million. The estimate indicates a year-over-year change of +70.3%.
Based on the collective assessment of analysts, 'Revenues- Solid Tumors- Tafinlar + Mekinist - Total' should arrive at $502.28 million. The estimate points to a change of +8% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Neuroscience- Gilenya - Total' should come in at $231.53 million. The estimate points to a change of -33.1% from the year-ago quarter.
Analysts forecast 'Revenues- Immunology-Cosentyx - Total' to reach $1.34 billion. The estimate indicates a year-over-year change of +23.7%.
The combined assessment of analysts suggests that 'Revenues- Hematology- Tasigna - US' will likely reach $228.84 million. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Hematology- Promacta/Revolade - US' reaching $263.34 million. The estimate points to a change of -6.6% from the year-ago quarter.
Analysts predict that the 'Revenues- Neuroscience- Gilenya - US' will reach $104.73 million. The estimate suggests a change of -44.6% year over year.
Analysts expect 'Revenues- Immunology- Cosentyx - US' to come in at $723.22 million. The estimate suggests a change of +14.3% year over year.
The consensus estimate for 'Revenues- Cardiovascular- Entresto - US' stands at $839.24 million. The estimate indicates a change of +20.9% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenues- Hematology- Tasigna - Rest of the world' of $233.24 million. The estimate indicates a change of -7.5% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Solid Tumors- Tafinlar + Mekinist - Rest of the world' will reach $296.24 million. The estimate points to a change of +2.2% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Hematology- Promacta/Revolade - Rest of the world' at $256.79 million. The estimate suggests a change of -0.5% year over year.
View all Key Company Metrics for Novartis here>>>
Over the past month, shares of Novartis have returned +7% versus the Zacks S&P 500 composite's +3.1% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>